<DOC>
	<DOCNO>NCT01060501</DOCNO>
	<brief_summary>The primary objective improve adjuvant 5-FU chemoradiotherapy resectable rectal cancer . The investigator hypothesis modulation 5-FU addition either FA INF-alpha may increase overall survival .</brief_summary>
	<brief_title>Modulation Adjuvant 5-FU Folinic Acid Interferon-alpha Colon Cancer</brief_title>
	<detailed_description>Primary endpoint overall survival ( OS ) . For sample size estimation follow assumption make : The 5-year OS rate 5-FU estimate 58 % . Our intention detect increase 5-year OS rate one additives least 10 % power 80 % level significance 5 % comparison 5-FU ( one-sided ) . Hypotheses analyzed pair wise comparison treatment option . This result target sample size 280 patient per group total 840 patient .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Eligibility define potentially curative enbloc resection ( R0 ) adenocarcinoma rectum low tumor edge within 12 cm anal verge determine rectoscopy , pathologic UICC stage II ( pT3/4pN0M0 ) III ( pT14pNposM0 ) examination least 12 lymph node , white blood count ≥ 3,500/µl , platelet count ≥ 100,000/µl , ECOG performance status 0 1 , write informed consent . Ineligible patient fulfil criterion history cancer except adequately treat superficial basal squamous cell skin cancer situ carcinoma cervix , get previous radio chemotherapy , pregnant nursing woman , severe concomitant disease limit life expectancy allow chemotherapy , social condition allow 5year followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1991</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>adjuvant chemoradiotherapy</keyword>
	<keyword>5-FU , interferon-alpha</keyword>
	<keyword>Locally advanced resectable rectal cancer ( UICC stage II III )</keyword>
</DOC>